Cargando…
Evaluation of Psoriasis Area and Severity Index as a Proxy for Biomarkers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles
The efficacy of psoriasis treatments is usually evaluated using the Psoriasis Area and Severity Index (PASI). However, there is a lack of systematic statistical assessments of PASI as a proxy for systemic disease in individual patients. Therefore, a retrospective study of 186 treatments with adalimu...
Autores principales: | HOFFMANN, Jochen H. O., KNOOP, Chriatian, SCHÄKEL, Knut, ENK, Alexander H., HADASCHIK, Eva N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367049/ https://www.ncbi.nlm.nih.gov/pubmed/33903917 http://dx.doi.org/10.2340/00015555-3814 |
Ejemplares similares
-
Detailed Long-term Dynamics of Neutrophil-to-Lymphocyte Ratio under Biologic Treatment Reveal Differential Effects of Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists
por: HOFFMANN, Jochen H. O., et al.
Publicado: (2021) -
Psoriasis Pathogenesis and Treatment
por: Rendon, Adriana, et al.
Publicado: (2019) -
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010) -
Inhibition of interleukin‐12 and/or interleukin‐23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
por: Ergen, Elizabeth N., et al.
Publicado: (2018) -
Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)